PTCT (STOCKS)
PTC Therapeutics, Inc.
$76.770000
+1.630000 (+2.17%)
Prev close: $75.140000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Matthew B. Klein
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $6,365.53M
- Employees
- 939
- P/E (TTM)
- -32.79
- P/B (TTM)
- -35.26
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
11
Buy
4
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.03 | $-0.48 | +0.4499 | +93.75% |
|
Dec 2025 (Q4)
|
$-1.67 | $0.04 | -1.7083 | -4,460.31% |
|
Sep 2025 (Q3)
|
$0.20 | $-1.40 | +1.5954 | +114.33% |
|
Jun 2025 (Q2)
|
$-0.83 | $-1.08 | +0.2526 | +23.33% |
Financial Statements
| Revenues | $827.11M |
| Benefits Costs and Expenses | $1.06B |
| Costs And Expenses | $1.06B |
| Operating Expenses | $885.44M |
| Selling, General, and Administrative Expenses | $352.37M |
| Research and Development | $447.15M |
| Other Operating Expenses | $85.93M |
| Operating Income/Loss | -$58.33M |
| Income/Loss From Continuing Operations After Tax | -$186.73M |
| Income/Loss From Continuing Operations Before Tax | -$235.67M |
| Income Tax Expense/Benefit | -$48.94M |
| Income Tax Expense/Benefit, Deferred | -$15.00K |
| Net Income/Loss | -$186.73M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$186.73M |
| Net Income/Loss Available To Common Stockholders, Basic | -$186.73M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.48 |
| Diluted Earnings Per Share | -$2.33 |
| Basic Average Shares | 240,035,194 |
| Diluted Average Shares | 249,199,399 |
| Assets | $2.87B |
| Current Assets | $2.25B |
| Accounts Receivable | $219.92M |
| Inventory | $75.57M |
| Other Current Assets | $1.96B |
| Noncurrent Assets | $615.10M |
| Fixed Assets | $52.74M |
| Intangible Assets | $380.68M |
| Other Non-current Assets | $181.68M |
| Liabilities | $3.05B |
| Current Liabilities | $923.60M |
| Accounts Payable | $25.48M |
| Wages | $33.84M |
| Other Current Liabilities | $864.28M |
| Noncurrent Liabilities | $2.13B |
| Equity | -$180.47M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$180.47M |
| Liabilities And Equity | $2.87B |
| Net Cash Flow From Operating Activities | -$217.95M |
| Net Cash Flow From Operating Activities, Continuing | -$217.95M |
| Net Cash Flow From Investing Activities | -$771.36M |
| Net Cash Flow From Investing Activities, Continuing | -$771.36M |
| Net Cash Flow From Financing Activities | $328.09M |
| Net Cash Flow From Financing Activities, Continuing | $328.09M |
| Net Cash Flow | -$661.22M |
| Net Cash Flow, Continuing | -$661.22M |
| Comprehensive Income/Loss | -$164.31M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$164.31M |
| Other Comprehensive Income/Loss | -$164.31M |
| Other Comprehensive Income/Loss Attributable To Parent | $22.42M |